The FDA has approved Cipla's nintedanib capsules as a new generic version of Ofev for treating idiopathic pulmonary fibrosis ...

Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in ...

The PFF's strategic plan includes several initiatives to make the community more inclusive of all forms of ILD, writes columnist Sam Kirton.

An IPF diagnosis left columnist Sam Kirton feeling lost, but thanks to several "navigation tools," he eventually found his way.

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Participants will be split into four dosing groups of eight people each. In each group, six people will receive a single into-the-vein injection of their assigned 9MW3811 dose, while the remaining two ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

In 2019 Christie Patient relocated to San Francisco to care for her mother, Holly, before and after her double-lung transplant. Holly’s idiopathic pulmonary fibrosis diagnosis came only months before ...